Interdisziplinäre AWMF-Leitlinie zur Therapie primärer Antikörpermangelerkrankungen

Zusammenfassung

Hintergrund:

Gegenwärtig unterscheidet sich die Versorgung von Patienten mit primären Antikörpermangelerkrankungen erheblich von Behandler zur Behandler. Zur Verbesserung der Versorgung wurde eine evidenz- und konsensusbasierte Leitlinie zur Therapie primärer Antikörpermangelerkrankungen entwickelt.

Methodik:

Auf dem Boden der aktuell bestehenden studienbasierten Evidenz (systematische Literaturrecherche über PubMed; Deadline November 2011) wurden mittels strukturierter Konsensusfindung (nominaler Gruppenprozess) während einer Konsensuskonferenz im November 2011 in Frankfurt 14 Kernaussagen verabschiedet. Die teilnehmenden Vertreter wurden durch ihre jeweilige Fachgesellschaft/Patientenorganisation nominiert ([Tab. 1]).

Tab. 1 Teilnehmende Fachgesellschaften und Verbände.

Arbeitsgemeinschaft Pädiatrische Immunologie e. V. (API)

Berufsverband der Kinder- und Jugendärzte e. V. (BVKJ)

Berufsverband der Niedergelassenen Hämatologen und Onkologen e. V. (BNHO)

Deutsche Gesellschaft für Hämatologie und Onkologie e. V. (DGHO)

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und ­Halschirurgie e. V.

Deutsche Gesellschaft für Immunologie e. V. (DGfI)

Deutsche Gesellschaft für Infektiologie e. V. (DGI)

Deutsche Gesellschaft für Innere Medizin (DGIM)

Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ)

Deutsche Gesellschaft für Kinder- und Jugendrheumatologie (DGKJ)

Deutsche Gesellschaft für Pädiatrische Infektiologie e. V. (DGPI)

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP)

Deutsche Gesellschaft für Rheumatologie e. V. (DGRh)

Deutsche Selbsthilfe Angeborene Immundefekte e. V. (dsai)

Deutscher Verband für Physiotherapie -Zentralverband der ­Physiotherapeuten/Krankengymnasten e. V. (ZVK)

Gesellschaft für Pädiatrische Onkologie und Hämatologie e. V. (GPOH)

Gesellschaft für Pädiatrische Pneumologie e. V. (GPP)

Österreichische Gesellschaft für Kinder- und Jugendheilkunde (ÖGKJ)

Schweizerische Gesellschaft für Allergologie und Immunologie (SGAI)

Schweizerische Gesellschaft für Pädiatrie/Swiss Society of Paediatrics (SGP)

Ergebnisse:

Die Empfehlungen der Leitlinie beziehen sich auf die Indikation, Durchführung und Steuerung der Immunglobulinsubstitutionstherapie sowie auf verschiedene Applikationsarten. Weiterhin werden Empfehlungen zu supportiven Maßnahmen wie antiinfektiöser Therapie, Impfungen und Physiotherapie gegeben. Die Kombination aus studienbasierter Evidenz und Expertenerfahrung in dieser evidenz- und konsensusbasierten Leitlinie ermöglicht eine Verbesserung der Versorgungsqualität für Patienten mit Antikörpermangelerkrankungen.

Abstract

Backround:

Currently, management of antibody deficient patients differs significantly among caregivers. Evidence and consensus based (S3) guidelines for the treatment of primary antibody deficiencies were developed to improve the management of these patients.

Methods:

Based on a thorough analysis of current evidence (systematic literature search in PubMed; deadline November 2011) 14 recommendations were finalized during a consensus meeting in Frankfurt in November 2011 using structured consensus methods (nominal group technique). Experts were nominated by their scientific societies/patient initiatives ([Tab. 1]).

Results:

The guidelines focus on indication, practical issues and monitoring of immunoglobulin replacement therapy as well as on different routes of administration. Furthermore recommendations regarding supportive measures such as antiinfective therapy, vaccinations and physiotherapy are given. Combining literature evidence and experience of caregivers within this evidence and consensus based guidelines offers the chance to improve the quality of care for anti­body deficient patients.

Schlüsselwörter

Primäre Antikörpermangel­erkrankungen - Leitlinie - Therapie - Immunglobuline - Kinder - Erwachsene

Key words

primary antibody ­deficiencies - guideline - therapy - immunoglobulins - children - adults

• Literatur

• 1 Abdou NI, Greenwell CA, Mehta R et al. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 2009; 149: 267-274
• 2 Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98: 1127-1131
• 3 Aghamohammadi A, Moin M, Farhoudi A et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004; 40: 113-118
• 4 Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011; 2: 54
• 5 Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112: 1-7
• 6 Berger M, Rojavin M, Kiessling P et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139: 133-141
• 7 Bernatowska E, Madalinski K, Janowicz W et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 1987; 43: 153-162
• 8 Bernatowska-Matuszkiewicz E, Pac M, Skopcynska H et al. Clinical efficacy of intravenous immunoglobulin in patients with severe inflammatory chest disease and IgG3 subclass deficiency. Clin Exp Immunol 1991; 85: 193-197
• 9 Blore J, Haeney MR. Primary antibody deficiency and diagnostic delay. BMJ 1989; 298: 516-517
• 10 Borte M, Oertelt C, Hogy B. Treatment of patients with primary antibody deficiencies in Germany. Klin Padiatr 2005; 217: 276-280
• 11 Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007; 27: 497-502
• 12 Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109: 1001-1004
• 13 Chapel HM, Christie JM, Peach V et al. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001; 99: 320-324
• 14 Chapel HM, Spickett GP, Ericson D et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94-100
• 15 Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34-48
• 16 Cunningham-Rundles C, Siegal FP, Smithwick EM et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984; 101: 435-439
• 17 Cunningham-Rundles C, Zhou Z, Mankarious S et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272-278
• 18 de Gracia J, Vendrell M, Alvarez A et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4: 745-753
• 19 Duse M, Iacobini M, Leonardi L et al. Transient hypogammaglobulinemia of infancy: intravenous immunoglobulin as first line therapy. Int J Immunopathol Pharmacol 2010; 23: 349-353
• 20 Eibl MM, Cairns L, Rosen FS. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes. Clin Immunol Immunopathol 1984; 31: 151-160
• 21 Farmand S, Baumann U, von Bernuth H et al. Interdisciplinary AWMF Guideline for the Diagnostics of Primary Immunodeficiency. Klin Padiatr 2011; 223: 378-385
• 22 Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96: 1474-1478
• 23 Gardulf A, Andersen V, Bjorkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365-369
• 24 Gardulf A, Bjorvell H, Andersen V et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients’ experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21: 917-927
• 25 Gardulf A, Borte M, Ochs HD et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126: 81-88
• 26 Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6: 434-442
• 27 Gardulf A, Nicolay U, Asensio O et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national study. J Clin Immunol 2006; 26: 177-185
• 28 Gardulf A, Nicolay U, Math D et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114: 936-942
• 29 Gathmann B, Binder N, Ehl S et al. The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol. 2012 167. 479-491
• 30 Gustafson R, Gardulf A, Granert C et al. Prophylactic therapy for selective IgA deficiency. Lancet 1997; 350: 865
• 31 Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005; 6: 24-29
• 32 Honig M, Schulz A, Friedrich W. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Klin Padiatr 2011; 223: 320-325
• 33 Jolles S, Bernatowska E, de Gracia J et al. Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011; 141: 90-102
• 34 Joshi AY, Iyer VN, Hagan JB et al. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc 2009; 84: 16-22
• 35 Kuntz M, Goldacker S, Blum HE et al. Analysis of bulk and virus-specific CD8+ T cells reveals advanced differentiation of CD8+ T cells in patients with common variable immunodeficiency. Clin Immunol 2011; 141: 177-186
• 36 Levy J, Espanol-Boren T, Thomas C et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 47-54
• 37 Liese JG, Wintergerst U, Tympner KD et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992; 146: 335-339
• 38 Lucas M, Lee M, Lortan J et al. Infection outcomes in patients with common variable immunedeficiency disorders relationship to ­immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125: 1354-1360
• 39 Nolte MT, Pirofsky B, Gerritz GA et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 1979; 36: 237-243
• 40 Ochs HD, Gupta S, Kiessling P et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26: 265-273
• 41 Oksenhendler E, Gerard L, Fieschi C et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46: 1547-1554
• 42 Olinder-Nielsen AM, Granert C, Forsberg P et al. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis 2007; 39: 44-50
• 43 Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117: S525-S553
• 44 Quartier P, Bustamante J, Sanal O et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol 2004; 110: 22-29
• 45 Quartier P, Debre M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999; 134: 589-596
• 46 Quinti I, Soresina A, Agostini C et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 2008; 28: 263-267
• 47 Quinti I, Soresina A, Spadaro G et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27: 308-316
• 48 Razvi S, Schneider L, Jonas MM et al. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 2001; 101: 284-288
• 49 Roifman CM, Lederman HM, Lavi S et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 1985; 79: 171-174
• 50 Roifman CM, Schroeder H, Berger M et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3: 1325-1333
• 51 Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005; 58: 546-547
• 52 Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973–93. Arch Dis Child 1996; 74: 527-530
• 53 Soderstrom T, Soderstrom R, Enskog A. Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency. Cancer 1991; 68: 1426-1429
• 54 STIKO: Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut . Hinweise zu Impfungen für Patienten mit Immundefizienz. Epidemiologisches Bulletin 2005;
• 55 Tarzi MD, Grigoriadou S, Carr SB et al. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155: 147-155
• 56 Thepot S, Malphettes M, Gardeur A et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30: 602-606
• 57 Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14: 90-97
• 58 Wasserman RL, Melamed I, Kobrynski L et al. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease. J Clin Immunol 2011; 31: 323-331
• 59 Winkelstein JA, Marino MC, Ochs H et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82: 373-384